Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

NRC Group ASA - Appointed to a contract in Sweden - SEK 117 million

The Swedish Transport Administration has appointed NRC Sverige AB, a company wholly owned by NRC Group ASA, to a contract for catenary work on the railway connection between Västerasby and Långsele. The contract is valued at approximately SEK 117 million, and will involve rail services such as electro and groundwork. The work will commence in April 2023 and is scheduled for completion in October 2024. Closing date for submission of complaints is 10 days from today, and formal contractual signing can take place after this period at the earliest. For further information, please

Diamyd Medical receives patent protection in the US and Japan for GABA formulation Remygen®

The US Patent and Trademark Office (USPTO) and the Japanese Patent Office have informed Diamyd Medical that they will grant the patent for the Company’s oral formulation of the GABA-based study drug Remygen[®]. Remygen[®] is currently in Phase 2 development through the ReGenerate-1 trial in individuals with long-term Type 1 Diabetes. Results are expected later this quarter.“The ongoing phase 2 trial ReGenerate-1 will guide us on how to move forward with Remygen”, says Ulf Hannelius, CEO of Diamyd Medical. “Patent protection for the formulation is important for all possible routes forward,

All-time-high net sales and strong cash flow

Fourth quarter: October – December · Net sales increased by 18 percent to383 MSEK (324) · Order intake amounted to 188 MSEK (484) · Order backlog amounted to 1 275 MSEK (1 557) · Operating profit amounted to 33 MSEK (38) · Adjusted operating profit amounted to 33 MSEK (38) · Net profit after tax amounted to 26 MSEK (30) · Earnings per share amounted to 1,38 SEK (1,36) · Operating cash flow amounted to 78 MSEK (126) Full year: January – December · Net sales increased by 19 percent to 1 334 MSEK (1 120) · Order intake amounted to 1 109 MSEK (1 558) ·

Wärtsilä appoints Saara Tahvanainen as Executive Vice President, Marketing and Communications and a member of the Wärtsilä Board of Management

Wärtsilä Corporation, Stock exchange release, February 6 2023 at 14:00 (EET)Wärtsilä appoints Saara Tahvanainen as Executive Vice President, Marketing and Communications and a member of the Wärtsilä Board of Management Wärtsilä has appointed Saara Tahvanainen (48), M.S.S., as Executive Vice President, Marketing and Communications and member of Board of Management. Ms Tahvanainen will commence in her role latest by the end of June 2023 and she will report to Wärtsilä’s President & CEO Håkan Agnevall. Ms Tahvanainen will succeed Mr Atte Palomäki, who will leave Wärtsilä with immediate

Correction message category: SpareBank 1 SR-Bank: SpareBank 1 Gruppen – result 4th quarter and the final year end 2022

SpareBank 1 SR-Bank has a 19.5% stake in SpareBank 1 Gruppen AS. SpareBank 1 SR-Bank majority share of SpareBank 1 Group's profit after tax in the 4th quarter was NOK 120 (173*) million. SpareBank 1 SR-Bank's majority share of profit as of 31 December 2022 was NOK 167 (471) million. SpareBank 1 Gruppen's consolidated profit before tax as of 31 December 2022 was NOK 1,399 (4,105) million. Profit after tax was NOK 1,137 (3,250) million. The majority's share of profit after tax in the 4th quarter and as of 31 December 2022 was respectively NOK 619 (888) and NOK 857 (2,415) million. The

Cyxone advances the patent portfolio for Rabeximod

Cyxone (publ), a biotech company in autoimmune diseases, is pleased to announce that national phase filings have been completed in a large number of relevant markets for four of its pending PCT applications directed to clinically applicable forms and formulations of Rabeximod, as well as their medical use, potentially conferring patent protection until 2041.In November 2020 Cyxone reported the filing of five new patent applications though the international patent cooperation treaty (PCT) in order to strengthen the intellectual property protection for Rabeximod. Cyxone today reports the

Invitation to presentation of Pexip Q4 2022 results

Pexip will present its fourth quarter results for 2022 on Tuesday, February 14, at 08:00 CET.The financial report and presentation material will be made available at 07:00 CET at investor.pexip.com and newsweb.no under the company’s ticker “PEXIP”. The presentation will be held by Trond K. Johannessen (CEO), Øystein Hem (CFO) and Åsmund Fodstad (Chief Revenue Officer) The presentation will be held in English and conducted as a webcast. Questions can be submitted to IR@pexip.com in advance of the presentation or live during the presentation. Please join

Metso Outotec to showcase its latest innovations and offering for the aggregates industry in CONEXPO-CON/AGG 2023

Metso Outotec Corporation’s press release on February 6, 2023, at 13:00 p.m. EETMetso Outotec will present its latest innovations, technologies and offering for the aggregates industry at the CONEXPO-CON/AGG 2023 international construction trade show taking place on March 14-18, 2023. "Throughout the whole aggregates and construction industry, sustainability is gaining ground and has become a big driver for innovations and operations,” says Juha Yli-Petäys, SVP, Global Distribution Management at Metso Outotec. “For us at Metso Outotec, sustainability and improved performance are among

Year-end report 2022

Increased rental income, improved net operating income and positive net lettings during all four quarters in 2022. Higher interest expenses and negative changes in value in the property portfolio during the fourth quarter meant that profit before tax decreased compared to the previous year.· Rental income amounted to SEK 3,032m (2,889). On a like-for-like basis, rental income increased by just over 5 per cent (2). · Net operating income amounted to SEK 2,240m (2,185). On a like-for-like basis, net operating income increased by 3 per cent (3). · The surplus ratio amounted to 74 per

3Shape rebrands FullContour to 3Shape Design Service

Copenhagen, February 6, 2023 – Today, 3Shape announced that it is adding design services to its portfolio of digital workflow solutions for dental labs. 3Shape solutions for labs now include award-winning 3Shape CAD-CAM design software, dental lab scanners, LabCare services, and the just-launched, 3Shape Design Service. FullContour rebrands to 3Shape Design Device, keeping leadership and personnel expertise The new 3Shape Design Service is a rebranding of the 3Shape owned, FullContour design service company. The move enables 3Shape to bring the former FullContour’s design services

2020 Bulkers Ltd. (2020) – Invitation to webcast and conference call Q4 2022 results

2020 Bulkers Ltd. will release its financial results for the fourth quarter of 2022 on Wednesday, February 8, 2023. A conference call and webcast will be held at 3:00 PM CET. The earnings report and presentation will be available from the Investor Relations section on www.2020bulkers.com on the same day. In order to listen to the presentation, you may do one of the following: Listen-only webcast (including the slide presentation): https://channel.royalcast.com/landingpage/hegnarmedia/20230208_9/ or you can click the “Webcast” link on www.2020bulkers.com/investor-relations/

Invitation to presentation of Bactiguard’s year-end report for 2022 on February 9, 2023

Bactiguard Holding AB (publ) publishes the year-end report for 2022 on Thursday February 9, 2023 at 08:00 CET.In connection with this, an audiocast for investors, analysts and media will be held at 10:00 CET on February 9, 2023. CEO Anders Göransson and CFO Carin Jakobson will present the interim report and answer questions. The report and a presentation for the audiocast will be available at Bactiguard’s website www.bactiguard.com . To participate in the audiocast, please use this link:https://www.bactiguard.com/report/q4-2022 To participate

SAS AB (publ) announces notice of the Annual General Meeting on 16 March 2023

Shareholders in SAS AB (publ) (the “Company”) are hereby invited to attend the Annual General Meeting on Thursday 16 March 2023. The Annual General Meeting will be held at 2:00 p.m. at the Company’s Head Office, Frösundaviks allé 1, Solna, Sweden. The meeting venue will open at 1:00 p.m. for registration. Registration of participants at the meeting ends when the meeting is called to order.   The Board has decided that the shareholders shall also be able to exercise their voting rights at the Annual General Meeting by postal voting in accordance with the Company’s Articles of Association.

SAGAX’S YEAR-END REPORT WILL BE PUBLISHED ON 17 OF FEBRUARY

Sagax’s Year-end Report 2022 will be published on Friday the 17 of February. In the interim report for the third quarter Monday the 13 of February was communicated. For further information, please contact CEO David Mindus, tel +46 8 545 83 540. About AB Sagax AB Sagax is a property company whose business concept is to invest in commercial properties, primarily in the warehouse and light industry segment. Sagax's property holdings per 30 September 2022 amounted to 4,036,000 square metres, distributed over 782 properties. AB Sagax (publ) is listed on Nasdaq Stockholm, Large Cap.

Invitation to the presentation of Latour’s year-end report 2022

Latour will publish the year-end report for 2022 on 10 February 2023 at 08.30 AM (CET). President and CEO Johan Hjertonsson will present the report and answer to questions together with CFO Anders Mörck on the same day at 10.00 (CET) in a webcasted telephone conference. WebcastVia the webcast you are able to ask written questions.If you wish to participate via webcast, please use the link: https://ir.financialhearings.com/latour-q4-2022 TeleconferenceYou can ask questions verbally via the teleconference. If you wish to participate via teleconference, please register on the

Webcast with Teleconference, Q4 / 2022

Nitro Games to host a Webcast on Monday 13 February 2023 09:30 Swedish time.Nitro Games Oyj Year-end Report for January - December 2022 will be released on Monday 13 February 2023. The Company will do a presentation after the release of the report. Participants can join this presentation by a Webcast. Participants can send questions to the presenters via email below. 13 February 2023 09:30 (Europe/Stockholm) Details of event: https://financialhearings.com/event/44212 Language: English Activity: Webcast Webcast: https://ir.financialhearings.com/nitro-games-q4-2022 Questions

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 34 - 6 EBRUARY 2023 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 230/22 and 233/22.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Thomas France, Investor Communications Partner, tel.: 3315 0451

DAMPSKIBSSELSKABET norden a/s – weekly report on share buy-back

ANNOUNCEMENT NO. 33 - 6 FEBRUARY 2023   On 3 November 2022, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 3 November 2022 up to and including no later than 7 February 2023. For details, please see announcement no. 230 of 3 November 2022.   Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 50 million (approximately DKK 380

Eevia Health Plc is awarded a business development grant of 243 KEUR

Eevia Health Plc (”Eevia” or ”The Company”) has received a positive decision from Business Finland for a business development grant of 243 840 EUR. The grant is a 50% financing of a total project budget of 487.680 EUR. The project has two work packages.One work package is aimed at increasing the scientific substantiation of the health effects of Eevia Health’s products. This will include a screening of the bioactivity of Eevia’s extracts using Eurofins BioMAP™. BioMAP™ profiling is the broadest, most physiologically relevant method to quickly and robustly determine the efficacy, safety, and

New terminal section at Göteborg Landvetter has now been officially inaugurated

Business leaders, political officials and representatives of government agencies and the aviation industry met on Friday 3rd of February at Göteborg Landvetter Airport under the scope of the regularly held TakeOff event. In conjunction, the airport’s new terminal section, the largest expansion in the airport’s history to date, was inaugurated. After a pause of several years, the popular TakeOff event was resumed and took place today at Göteborg Landvetter Airport with some 120 participants in attendance. Jonas Abrahamsson, Swedavia’s president and CEO, and Anna Strömwall, the airport

BioStock: Annexin's CEO: "The cancer area more than doubles the potential"

Annexin Pharmaceuticals' candidate ANXV is being developed as a new treatment for retinal vein occlusion, an eye disease that affects more than 16 million people globally. However, the candidate has also shown promising potential in cancer, among other indications, and the Stockholm-based company has recently stepped into the field. BioStock spoke with CEO Anders Haegerstrand to get his take on the potential for ANXV in cancer.Read the interview with Annexin Pharmaceuticals at biostock.se: https://www.biostock.se/en/2023/02/annexins-ceo-the-cancer-area-more-than-doubles-the-potential (

Konecranes Plc - Managers' transactions - Christoph Vitzthum

Konecranes Plc - Managers' transactions - Christoph Vitzthum____________________________________________ Person subject to the notification requirementName: Vitzthum, ChristophPosition: Member of the Board/Deputy memberIssuer: Konecranes PlcLEI: 549300EF0CDEQZBMA096 Notification type: INITIAL NOTIFICATIONReference number: 549300EF0CDEQZBMA096_20230203142723_322____________________________________________ Transaction date: 2023-02-03Venue: XHELInstrument type: SHAREISIN: FI0009005870Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction

Quartr signs a deal with Nordnet, the leading online broker in the Nordic region

Finance software startup Quartr signs an API deal with Nordnet, the leading online broker in the Nordic region, reaching their almost two million customers. The partnership grants Nordnet access to Quartr’s database of earnings calls, slide decks, reports, and financial segment data, providing its customers with a strong foundation to make informed investment decisions. At the same time, this creates a much wider and completely new distribution channel for the information that public companies provide.STOCKHOLM & NEW YORK - Quartr (www.quartr.com) has passed an additional milestone on its

There are no items matching the current filter
There are no more items matching the current filter
Back to top